Cancer du sein : diagnostic et traitement

11 septembre 2014

Dans cet article

Auteurs, liens et références

Auteur :

Cet article a été adapté de la revue Breast Cancer originalement publiée sur Medscape.com.

Auteurs et collaborateurs :

Information complète sur les auteurs, disponible ici.

Traduction et adaptation :

Aurore Blésius, Docteur en oncologie médicale.

Liens d’intérêts : aucun

Références
  1. Mulcahy N. Practice changing: drug preserves fertility during chemo. Medscape Medical News [serial online]. May 30, 2014 http://www.medscape.com/viewarticle/825989.

  2. Moore HCF, Unger JM, Phillips KA, Boyle FM, Hitre E, Porter DJ, et al. Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international intergroup trial of SWOG, IBCSG, ECOG, and CALGB. Abstract LBA505. Presented May 31, 2014, at the 2014 annual meeting of the American Society of Clinical Oncology. American Society of Clinical Oncology. Available at http://meetinglibrary.asco.org/content/129172-144.

  3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. Mar-Apr 2011;61(2):69-90.

  4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. Jan 2013;63(1):11-30.

  5. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. Oct 4 2012;490(7418):61-70. [Full Text].

  6. [Guideline] Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. Mar 1 2001;19(5):1539-69.

  7. Surveillance Epidemiology and End Results (SEER). SEER Stat Fact Sheets: Breast. http://seer.cancer.gov/statfacts/html/breast.html#incidence-mortality.

  8. Jatoi I, Anderson WF, Rosenberg PS. Qualitative age-interactions in breast cancer: a tale of two diseases? doi: 10.1097/COC.0b013e3181844d1c. Am J Clin Oncol. Oct 2008;31(5):504-6.

  9. Parmigiani G, Chen S, Iversen ES Jr, Friebel TM, Finkelstein DM, Anton-Culver H, et al. Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med. Oct 2 2007;147(7):441-50. [Full Text].

  10. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. Dec 15 2005;104(12):2807-16.

  11. Kelsey JL, Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health. 1996;17:47-67.

  12. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol. Nov 15 2000;152(10):950-64.

  13. Deligeoroglou E, Michailidis E, Creatsas G. Oral contraceptives and reproductive system cancer. Ann N Y Acad Sci. Nov 2003;997:199-208.

  14. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. Feb 4 2004;96(3):218-28.

  15. Pike MC, Pearce CL, Peters R, Cozen W, Wan P, Wu AH. Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril. Jul 2004;82(1):186-95.

  16. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst. Oct 4 2006;98(19):1406-15.

  17. Hankinson SE, Eliassen AH. Circulating sex steroids and breast cancer risk in premenopausal women. Horm Cancer. Feb 2010;1(1):2-10. [Full Text].

  18. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. May 2011;12(5):496-503.

  19. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. Nov 16 2005;97(22):1652-62. [Full Text].

  20. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. Sep 16 1998;90(18):1371-88.

  21. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. Jun 21 2006;295(23):2727-41.

  22. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. Apr 17 2002;94(8):606-16.

  23. Santen RJ, Boyd NF, Chlebowski RT, Cummings S, Cuzick J, Dowsett M, et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer. Jun 2007;14(2):169-87.

  24. Endogenous Hormones and Breast Cancer Collaborative Group. Free estradiol and breast cancer risk in postmenopausal women: comparison of measured and calculated values. Cancer Epidemiol Biomarkers Prev. Dec 2003;12(12):1457-61.

  25. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. Jun 27 2002;346(26):2025-32.

  26. Garbe E, Levesque L, Suissa S. Variability of breast cancer risk in observational studies of hormone replacement therapy: a meta-regression analysis. Maturitas. Mar 15 2004;47(3):175-83.

  27. Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol. Nov 2006;7(11):910-8.

  28. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. Jan 26 2000;283(4):485-91.

  29. Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. May 2012;13(5):476-86. [Full Text].

  30. Speroff L. The Million Women Study and breast cancer. Maturitas. Sep 25 2003;46(1):1-6.

  31. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. Lancet. Feb 7 2004;363(9407):453-5.

  32. Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR, Hatfield AK, Nelimark RA, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. Aug 11 1994;331(6):347-52.

  33. Bordeleau L, Pritchard K, Goodwin P, Loprinzi C. Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. Clin Ther. Feb 2007;29(2):230-41.

  34. Page DL, Jensen RA. Evaluation and management of high risk and premalignant lesions of the breast. World J Surg. Jan-Feb 1994;18(1):32-8.

  35. Kollias J, Ellis IO, Elston CW, Blamey RW. Clinical and histological predictors of contralateral breast cancer. Eur J Surg Oncol. Dec 1999;25(6):584-9.

  36. Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD Jr, Simpson JF. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. Jan 11 2003;361(9352):125-9.

  37. Page DL. Breast lesions, pathology and cancer risk. Breast J. Jan-Feb 2004;10 Suppl 1:S3-4.

  38. Ashbeck EL, Rosenberg RD, Stauber PM, Key CR. Benign breast biopsy diagnosis and subsequent risk of breast cancer. Cancer Epidemiol Biomarkers Prev. Mar 2007;16(3):467-72.

  39. Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol. Jul 1 2007;25(19):2671-7.

  40. Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD Jr, Rados MS, et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med. Jul 7 1994;331(1):10-5.

  41. Henderson BE, Bernstein L. The international variation in breast cancer rates: an epidemiological assessment. Breast Cancer Res Treat. May 1991;18 Suppl 1:S11-7.

  42. Kaaks R. Nutrition, hormones, and breast cancer: is insulin the missing link?. Cancer Causes Control. Nov 1996;7(6):605-25.

  43. Stoll BA. Breast cancer and the western diet: role of fatty acids and antioxidant vitamins. Eur J Cancer. Nov 1998;34(12):1852-6.

  44. Holmes MD, Liu S, Hankinson SE, Colditz GA, Hunter DJ, Willett WC. Dietary carbohydrates, fiber, and breast cancer risk. Am J Epidemiol. Apr 15 2004;159(8):732-9.

  45. Holmes MD, Willett WC. Does diet affect breast cancer risk?. Breast Cancer Res. 2004;6(4):170-8. [Full Text].

  46. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA. Jul 12 2006;296(2):193-201.

  47. Han D, Nie J, Bonner MR, McCann SE, Muti P, Trevisan M, et al. Lifetime adult weight gain, central adiposity, and the risk of pre- and postmenopausal breast cancer in the Western New York exposures and breast cancer study. Int J Cancer. Dec 15 2006;119(12):2931-7.

  48. Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. Novartis Found Symp. 2004;262:247-60; discussion 260-68.

  49. Lukanova A, Lundin E, Zeleniuch-Jacquotte A, Muti P, Mure A, Rinaldi S, et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol. Feb 2004;150(2):161-71.

  50. Baer HJ, Colditz GA, Rosner B, Michels KB, Rich-Edwards JW, Hunter DJ, et al. Body fatness during childhood and adolescence and incidence of breast cancer in premenopausal women: a prospective cohort study. Breast Cancer Res. 2005;7(3):R314-25. [Full Text].

  51. Ruder EH, Dorgan JF, Kranz S, Kris-Etherton PM, Hartman TJ. Examining breast cancer growth and lifestyle risk factors: early life, childhood, and adolescence. Clin Breast Cancer. Aug 2008;8(4):334-42. [Full Text].

  52. Fuemmeler BF, Pendzich MK, Tercyak KP. Weight, dietary behavior, and physical activity in childhood and adolescence: implications for adult cancer risk. Obes Facts. 2009;2(3):179-86. [Full Text].

  53. Laden F, Hunter DJ. Environmental risk factors and female breast cancer. Annu Rev Public Health. 1998;19:101-23.

  54. Coyle YM. The effect of environment on breast cancer risk. Breast Cancer Res Treat. Apr 2004;84(3):273-88.

  55. Gammon MD, Eng SM, Teitelbaum SL, Britton JA, Kabat GC, Hatch M, et al. Environmental tobacco smoke and breast cancer incidence. Environ Res. Oct 2004;96(2):176-85.

  56. Smith-Bindman R. Environmental causes of breast cancer and radiation from medical imaging: findings from the Institute of Medicine report. Arch Intern Med. Jul 9 2012;172(13):1023-7.

  57. Carmichael A, Sami AS, Dixon JM. Breast cancer risk among the survivors of atomic bomb and patients exposed to therapeutic ionising radiation. Eur J Surg Oncol. Jun 2003;29(5):475-9.

  58. Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev. Aug 2000;26(4):291-302.

  59. Hill DA, Gilbert E, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood. Nov 15 2005;106(10):3358-65. [Full Text].

  60. American Cancer Society. Breast Cancer Facts & Figures 2011-2012. Available at http://www.cancer.org/Research/CancerFactsFigures/BreastCancerFactsFigures/breast-cancer-facts-and-figures-2011-2012.

  61. Li CI, Daling JR. Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev. Dec 2007;16(12):2773-80.

  62. Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. Aug 1 2007;99(15):1152-61.

  63. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007;9(3):R28. [Full Text].

  64. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. Apr 19 2007;356(16):1670-4.

  65. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat. Feb 2008;107(3):427-30.

  66. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. Aug 9 2003;362(9382):419-27.

  67. Anderson WF, Reiner AS, Matsuno RK, Pfeiffer RM. Shifting breast cancer trends in the United States. J Clin Oncol. Sep 1 2007;25(25):3923-9.

  68. Evidence-based assessment of the impact of the WHI on women's health. doi: 10.3109/13697137.2012.655564. Burger HG, MacLennan AH, Huang KE, Castelo-Branco C. Climacteric. Jun 2012;15(3):281-7.

  69. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer, v.1.2012. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

  70. Baselga J, Seidman AD, Rosen PP, Norton L. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Williston Park). Mar 1997;11(3 Suppl 2):43-8.

  71. Nassar H, Wallis T, Andea A, Dey J, Adsay V, Visscher D. Clinicopathologic analysis of invasive micropapillary differentiation in breast carcinoma. Mod Pathol. Sep 2001;14(9):836-41.

  72. Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol. Apr 1999;10(4):413-9.

  73. Chao TC, Wang CS, Chen SC, Chen MF. Metaplastic carcinomas of the breast. J Surg Oncol. Aug 1999;71(4):220-5.

  74. Chaudary MA, Millis RR, Lane EB, Miller NA. Paget's disease of the nipple: a ten year review including clinical, pathological, and immunohistochemical findings. Breast Cancer Res Treat. 1986;8(2):139-46.

  75. Kollmorgen DR, Varanasi JS, Edge SB, Carson WE 3rd. Paget's disease of the breast: a 33-year experience. J Am Coll Surg. Aug 1998;187(2):171-7.

  76. Brooks M. BRCA Testing Update: 'Do This, Don't Do That.'. Medscape Medical News. http://www.medscape.com/viewarticle/818267.

  77. [Guideline] Moyer VA. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. Dec 24 2013;

  78. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. Oct 27 2005;353(17):1784-92.

  79. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA. Mar 9 2005;293(10):1245-56. [Full Text].

  80. Chustecka Z. FDA Warning on Nipple Aspirate Test as Breast Cancer Screen. Medscape Medical News [serial online]. Dec 13 2013; http://www.medscape.com/viewarticle/817806.

  81. Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. Mar 16 2002;359(9310):909-19.

  82. Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet. Apr 26 2003;361(9367):1405-10.

  83. Noble M, Bruening W, Uhl S, Schoelles K. Computer-aided detection mammography for breast cancer screening: systematic review and meta-analysis. Arch Gynecol Obstet. Jun 2009;279(6):881-90.

  84. Barclay L. Digital mammography: direct outperforms computed radiography. Medscape Medical News [serial online]. May 14, 2013; http://www.medscape.com/viewarticle/804094.

  85. Chiarelli AM, Edwards SA, Prummel MV, Muradali D, Majpruz V, Done SJ, et al. Digital compared with screen-film mammography: performance measures in concurrent cohorts within an organized breast screening program. Radiology. May 14 2013;

  86. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. Sep 3 2002;137(5 Part 1):347-60.

  87. Ward E, Jemal A, Thun M. Regarding "Increase in breast cancer incidence in middle-aged women during the 1990s". Ann Epidemiol. Jul 2005;15(6):424-5; author reply 426-7.

  88. US Preventive Services Task Force. Screening for Breast Cancer. http://www.uspreventiveservicestaskforce.org/uspstf/uspsbrca.htm.

  89. Smith RA, Saslow D, Sawyer KA, Burke W, Costanza ME, Evans WP 3rd, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin. May-Jun 2003;53(3):141-69.

  90. Taillefer R. Clinical applications of 99mTc-sestamibi scintimammography. Semin Nucl Med. Apr 2005;35(2):100-15.

  91. Chen AC, Paulino AC, Schwartz MR, Rodriguez AA, Bass BL, Chang JC, et al. Prognostic markers for invasive micropapillary carcinoma of the breast: a population-based analysis. Clin Breast Cancer. Apr 2013;13(2):133-9.

  92. National Comprehensive Cancer Network Practice Guidelines. Invasive Breast Cancer. 2009. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf.

  93. [Guideline] Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. Jan 1 2007;25(1):118-45.

  94. Tang G, Cuzick J, Costantino JP, Dowsett M, Forbes JF, Crager M, et al. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol. Nov 20 2011;29(33):4365-72.[Full Text].

  95. Johnson K. For node-positive breast cancer, axillary radiation is best. Medscape Medical News [serial online]. June 6, 2013; http://www.medscape.com/viewarticle/805406.

  96. Haviland JS, Owen JR, Dewar JA, et al, on behalf of the START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. Sep 18 2013;

  97. Mulcahy N. Ten-year data confirm shorter radiotherapy best for breast cancer. Medscape Medical News [serial online]. September 19, 2013;Accessed September 20, 2013. Available at http://www.medscape.com/viewarticle/811285.

  98. Chustecka Z. New guideline on lumpectomy margins should reduce re-excision. Medscape Medical News [serial online]. February 11, 2014; http://www.medscape.com/viewarticle/820474.

  99. [Guideline] Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. Int J Radiat Oncol Biol Phys. Mar 1 2014;88(3):553-64.

  100. American Society of Breast Surgeons. Consensus Statement for Accelerated Partial Breast Irradiation. https://www.breastsurgeons.org/statements/PDF_Statements/APBI.pdf.

  101. Mulcahy N. Is whole-breast radiation better in older women?. Medscape Medical News [serial online]. February 6, 2014; http://www.medscape.com/viewarticle/820272.

  102. Smith GL, Jiang J, Buchholz TA, Xu Y, Hoffman KE, Giordano SH, et al. Benefit of adjuvant brachytherapy versus external beam radiation for early breast cancer: impact of patient stratification on breast preservation. Int J Radiat Oncol Biol Phys. Feb 1 2014;88(2):274-84.

  103. Kuske RR, Young SS. Breast brachytherapy versus whole-breast irradiation: reported differences may be statistically significant but clinically trivial. Int J Radiat Oncol Biol Phys. Feb 1 2014;88(2):266-8.

  104. Mulcahy N. 'One-Stop' Radiotherapy Saves Time With Breast Cancer. M. http://www.medscape.com/viewarticle/814157.

  105. Mulcahy N. 'One-Stop' Radiotherapy Saves Time With Breast Cancer. Medscape Medical News. http://www.medscape.com/viewarticle/814157

  106. Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. Nov 8 2013;

  107. Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. Nov 8 2013;

  108. Ebctcg Early Breast Cancer Trialists' Collaborative Group. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. Mar 19 2014;[Medline].

  109. Chustecka Z. Radiotherapy for Early Breast Cancer and 1 to 3 Positive Nodes. Medscape [serial online]. http://www.medscape.com/viewarticle/822213.

  110. Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. Apr 20 2012;30(12):1268-73. [Full Text].

  111. Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, et al. Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. J Clin Oncol. Sep 1 2013;31(25):3091-3099.

  112. Nelson R. Tamoxifen Cuts Risk for Breast Cancer in BRCA Carriers. Medscape [serial online]. http://www.medscape.com/viewarticle/809174.

  113. ClinicalTrials.gov. Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341142/.

  114. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. Jan 2012;13(1):25-32.

  115. Barclay L. New ASCO Guidelines Address HER2-Positive Breast Cancer. Medscape Medical News [serial online]. May 7 2014; http://www.medscape.com/viewarticle/824751.

  116. [Guideline] Giordano SH, Temin S, Kirshner JJ, et al. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. May 5 2014;

  117. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. May 1 2006;24(13):2019-27.

  118. Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, et al. Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. Jul 8 2013;

  119. Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. Jun 23 2011;364(25):2381-91.

Commenter

3090D553-9492-4563-8681-AD288FA52ACE
Les commentaires peuvent être sujets à modération. Veuillez consulter les Conditions d'utilisation du forum.

Traitement....